Hoffmann-La Roche Inc.

Roche Glycart Ag

F. Hoffmann-La Roche Ag

Inja Waldhauer

Christian Klein

Ekkehard Moessner

Ralf Hosse

Pablo Umana

Stefan Seeber

Pablo Umaña

Anne Freimoser-Grundschober

Valeria G Nicolini

Wolfgang Richter

Alexander Knaupp

Halina Trochanowska

Guy Georges

Peter Bruenker

Claudia Ferrara Koller

Thomas U Hofer

Joerg Moelleken

Sandra Grau-Richards

Huisheng Wang

Kathryn Elizabeth Packman

Maximiliane Koenig

Barbara Weiser

Laura Codarri Deak

Valeria Runza

Huifeng Niu

Maria Valeria Gonzalez Nicolini

Sherif Daouti

Laura Lauener

Ningping Feng

Stefan Dengl

Sylvia Herter

Sandra Grau

Christoph Lampert

The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to CD3 and CD19

The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.

Immunoconjugates

The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to NKG2D

The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and TYRP-1

The present invention generally relates to antibodies that bind to CD3, including multi specific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Bispecific antibody molecules binding to CD3 and EGFRvIII

The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Antibodies specific for DR5 and methods of use

Bispecific antibodies specific for FAP and DR5, antibodies specific for DR5

The present invention relates to bispecific antibodies comprising a first antigen binding site specific for a death receptor and a second antigen binding site specific for a second antigen, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

DR5&#x2014;FAP bispecific death receptor agonistic antibodies

Growing community of inventors

Urdorf, Switzerland

Inja Waldhauer